Is Viking Therapeutics (VKTX) Fully Valued On Its Positive VK2735 Trial Update?

Viking Therapeutics (VKTX) is back in focus after reporting positive top-line data from its VK2735 obesity maintenance trial, where participants maintained significant weight loss on less frequent dosing schedules with a safety profile comparable to placebo.

The positive VK2735 update comes on top of a powerful run for Viking Therapeutics, with a 7 day share price return of 40.92% and a 1 year total shareholder return of 56.21%. The 5 year total shareholder return of more than 7x also points to strong long term momentum.

Scan beyond Viking Therapeutics and review hand-picked obesity and metabolic drug developers on our 38 healthcare AI stocks to see how the market is treating other high-momentum trial stories.

The latest surge in Viking Therapeutics looks tightly linked to VK2735 trial excitement, not any shift in current revenues. The real issue now is how much of that trial optimism is already reflected in the valuation.

Price-to-Book of 11.9x: Is Viking Therapeutics' Premium Justified?

Valuation has raced to catch up with the VK2735 headlines, and Viking Therapeutics now trades at a P/B multiple that is far above its peers while still generating no revenue and remaining loss making.

The preferred metric here is the price-to-book ratio, which compares the market value of the equity to the firm’s reported net assets on the balance sheet. For a clinical stage biotech with no product sales, investors often lean on P/B because traditional earnings based measures like P/E are not workable during extended periods of losses.

Viking Therapeutics currently carries a P/B of 11.9x according to Simply Wall St’s checks. The broader US biotechs group is cited at 2.2x and the peer average at 4.3x, so the stock is trading at a steep premium to both the wider industry and closer comparables. That gap suggests the market is already pricing in a lot of future success for the pipeline, which leaves less room for error if trial outcomes, timelines, or funding needs do not line up with those expectations.

On these figures the valuation looks stretched relative to both industry and peer benchmarks, so anyone buying in today is effectively paying well above book value for optionality on the clinical assets rather than current financial performance.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 11.9x (OVERVALUED)

Still, the story around Viking Therapeutics can change quickly if VK2735 data disappoints in later stages or if ongoing losses of $534.796 million pressure future funding options.

Find out about the key risks to this Viking Therapeutics narrative.

Another View on Viking Therapeutics' Value

The 11.9x P/B valuation multiple tells one story for Viking Therapeutics. The SWS DCF model tells another. On estimated future cash flows, VKTX at $41.60 trades well above a DCF value of $7.51, which indicates a sharply overvalued setup under that framework.

Both methods suggest that a lot of optimism may already be reflected in the price, yet they approach the question from different angles. The key question for anyone looking at Viking Therapeutics is which lens they consider more informative when expectations are already embedded in the valuation.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Viking Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 30 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Feeling cautious after reading this Viking Therapeutics review is reasonable, especially with so much optimism already priced in. Act while the data is fresh in mind by weighing those expectations against the 4 important warning signs.

Looking for more ideas beyond Viking Therapeutics?

If Viking Therapeutics has you rethinking risk and reward, broaden your watchlist with fresh stock ideas filtered by quality, value, and balance sheet strength.

• Target potential bargains with resilient cash generators by scanning our 30 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies in the 7 dividend fortresses that currently offer higher yields.
• Prioritise resilience by checking the list of solid balance sheet and fundamentals (23 results) before the next bout of volatility catches you off guard.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com